Immunexpress, Debiopharm and Biocartis have signed a worldwide exclusive, royalty-bearing licence for the late-stage development and commercialisation of SeptiCyte triage, a multiplex gene expression assay for use in emergency and intensive care units (ICUs) or upon hospital admission to diagnose sepsis early, differentiate sepsis from other forms of inflammation and determine sepsis severity.
Under the terms of the agreement, Debiopharm will fund the testing and FDA clearance of SeptiCyte triage and Biocartis will subsequently fund the development and commercialisation of the SeptiCyte triage assay on its integrated molecular diagnostics platform. The latter, which includes an instrument, communication console and single-use, disposable cartridges, can detect and quantify multiple DNA- or RNA-based biomarkers in a wide variety of patient sample types with minimal user intervention in less than 90 minutes. As part of the agreement, Debiopharm will make an equity investment in Immunexpress of A$2 million (US$2.04 million).
Immunexpress' SeptiCyte technology quantifies specific and multiple molecular markers from the patient's own immune system ('host response') for earlier detection, severity assessment, and better timing and targeting of drug and other therapies. By translating and quantifying complex molecular signals in an objective score, SeptiCyte technology provides reports on disease probabilities, enabling clinicians to better manage sepsis patients for improved patient outcomes. The technology forms the basis for three products - SeptiCyte triage, SeptiCyte STAT and SeptiCyte RTT - which are intended for use on the Biocartis platform in a variety of critical care hospital settings, but will also be available for other standard hospital laboratory platforms.